Risedronate (BioDeep_00000006687)

human metabolite blood metabolite Chemicals and Drugs

代谢物信息卡片

[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid

化学式: C7H11NO7P2 (283.0010756)
中文名称: 利塞膦酸
谱图信息: 最多检出来源 Mus musculus(blood) 26.32%

分子结构信息

SMILES: C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
InChI: InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)

描述信息

Risedronate is only found in individuals that have used or taken this drug. It is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Pagets disease of bone.The action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
M - Musculo-skeletal system > M05 - Drugs for treatment of bone diseases > M05B - Drugs affecting bone structure and mineralization > M05BA - Bisphosphonates
C78281 - Agent Affecting Musculoskeletal System > C67439 - Bone Resorption Inhibitor
D050071 - Bone Density Conservation Agents > D004164 - Diphosphonates
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers
D000077264 - Calcium-Regulating Hormones and Agents
D049990 - Membrane Transport Modulators

同义名列表

20 个代谢物同义名

[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid; 2-(3-Pyridinyl)-1-hydroxyethylidene-bisphosphonate; 2-(3-Pyridinyl)-1-hydroxyethylidenebisphosphonate; 1-Hydroxy-2-(3-pyridyl)ethylidene diphosphonate; Risedronate sodium, bisphosphonate; Sodium, bisphosphonate risedronate; Bisphosphonate risedronate sodium; Sodium, bisphosphate risedronate; Risedronate sodium, bisphosphate; Risedronic acid, monosodium salt; Bisphosphate risedronate sodium; Sodium, risedronate; Risedronate sodium; Acid, risedronic; Risedronic acid; Risedronate; NE-58095; Atelvia; Actonel; Ridron

数据库引用编号

18 个数据库交叉引用编号

ChEBI: CHEBI:8869
KEGG: C08233
KEGGdrug: D08484
PubChem: 5245
HMDB: HMDB0015022
Metlin: METLIN85024
Metlin: METLIN66852
DrugBank: DB00884
ChEMBL: CHEMBL923
Wikipedia: Risedronic acid
MeSH: Risedronic Acid
chemspider: 5055
CAS: 105462-24-6
PMhub: MS000019767
PubChem: 10432
PDB-CCD: RIS
NIKKAJI: J476.065D
RefMet: Risedronate

分类词条

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 - Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

文献列表

Pengfei Li, Xiaojian Wu, Ye Li, Jianhua Huang. Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis. Clinical and investigative medicine. Medecine clinique et experimentale. 2022 09; 45(3):E14-22. doi: 10.25011/cim.v45i3.38875. [PMID: 36149052]
Diane Kleinermans, Andrew Joyson, Heather Wray. An open-label randomized study of the relative absorption of gastro-resistant risedronate taken fasted or with food versus immediate-release risedronate. Pharmacology research & perspectives. 2022 06; 10(3):e00957. doi: 10.1002/prp2.957. [PMID: 35526121]
Nancy Waltman, Kevin A Kupzyk, Laura E Flores, Lynn R Mack, Joan M Lappe, Laura D Bilek. Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2022 Feb; 33(2):475-486. doi: 10.1007/s00198-021-06083-2. [PMID: 34519832]
Guo-Dong Zhao, Rong Gao, Xiao-Tao Hou, Hui Zhang, Xu-Tao Chen, Jin-Quan Luo, Hui-Fei Yang, Tong Chen, Xue Shen, Shi-Cong Yang, Cheng-Lin Wu, Gang Huang. Endoplasmic Reticulum Stress Mediates Renal Tubular Vacuolation in BK Polyomavirus-Associated Nephropathy. Frontiers in endocrinology. 2022; 13(?):834187. doi: 10.3389/fendo.2022.834187. [PMID: 35464062]
B Cardozo, E Karatza, V Karalis. Osteoporosis treatment with risedronate: a population pharmacokinetic model for the description of its absorption and low plasma levels. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2021 Nov; 32(11):2313-2321. doi: 10.1007/s00198-021-05944-0. [PMID: 34002251]
Luca Degli Esposti, Valentina Perrone, Diego Sangiorgi, Margherita Andretta, Fausto Bartolini, Arturo Cavaliere, Andrea Ciaccia, Stefania Dell'orco, Stefano Grego, Sara Salzano, Loredana Ubertazzo, Adriano Vercellone, Davide Gatti, Angelo Fassio, Ombretta Viapiana, Maurizio Rossini, Giovanni Adami. The Use of Oral Amino-Bisphosphonates and Coronavirus Disease 2019 (COVID-19) Outcomes. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2021 11; 36(11):2177-2183. doi: 10.1002/jbmr.4419. [PMID: 34405441]
Mi Yeong Kim, Kyunghee Lee, Hong-In Shin, Kyung-Jae Lee, Daewon Jeong. Metabolic activities affect femur and lumbar vertebrae remodeling, and anti-resorptive risedronate disturbs femoral cortical bone remodeling. Experimental & molecular medicine. 2021 01; 53(1):103-114. doi: 10.1038/s12276-020-00548-w. [PMID: 33436949]
Xiaofeng Xu, Wenyu Hui, Nian Liu, Yong Zhang. Effects of ergosteroside combined risedronate on fracture healing and BMP-2, BMP-7 and VEGF expression in rats. Acta cirurgica brasileira. 2021; 36(11):e361107. doi: 10.1590/acb361107. [PMID: 34932671]
Hachemi Kadri, Taher E Taher, Qin Xu, Maria Sharif, Elizabeth Ashby, Richard T Bryan, Benjamin E Willcox, Youcef Mehellou. Aryloxy Diester Phosphonamidate Prodrugs of Phosphoantigens (ProPAgens) as Potent Activators of Vγ9/Vδ2 T-Cell Immune Responses. Journal of medicinal chemistry. 2020 10; 63(19):11258-11270. doi: 10.1021/acs.jmedchem.0c01232. [PMID: 32930595]
Hiroaki Ishida, Hirotaka Komaba, Naoto Hamano, Hideyuki Yamato, Kaichiro Sawada, Takehiko Wada, Michio Nakamura, Masafumi Fukagawa. Skeletal and mineral metabolic effects of risedronate in a rat model of high-turnover renal osteodystrophy. Journal of bone and mineral metabolism. 2020 Jul; 38(4):501-510. doi: 10.1007/s00774-020-01095-0. [PMID: 32140785]
Kousuke Iba, Junichi Takada, Tomoko Sonoda, Toshihiko Yamashita. Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. Journal of bone and mineral metabolism. 2020 Mar; 38(2):240-247. doi: 10.1007/s00774-019-01049-1. [PMID: 31667583]
Chengzhi Yang, Guoping Le, Changwei Lu, Renjie Wei, Wanjie Lan, Jingli Tang, Xinli Zhan. Effects of teriparatide compared with risedronate in the treatment of osteoporosis: A meta-analysis of randomized controlled trials. Medicine. 2020 Feb; 99(7):e19042. doi: 10.1097/md.0000000000019042. [PMID: 32049802]
Yanhua Deng, Lin Li, Ceng Li, Fang Wang, Yang Qu. Efficacy of combined medication of risedronate sodium and selective estrogen receptor modulator on the postmenopausal osteoporosis. Pakistan journal of pharmaceutical sciences. 2020 Jan; 33(1(Special)):495-498. doi: . [PMID: 32173648]
Robert B Conley, Gemma Adib, Robert A Adler, Kristina E Åkesson, Ivy M Alexander, Kelly C Amenta, Robert D Blank, William Timothy Brox, Emily E Carmody, Karen Chapman-Novakofski, Bart L Clarke, Kathleen M Cody, Cyrus Cooper, Carolyn J Crandall, Douglas R Dirschl, Thomas J Eagen, Ann L Elderkin, Masaki Fujita, Susan L Greenspan, Philippe Halbout, Marc C Hochberg, Muhammad Javaid, Kyle J Jeray, Ann E Kearns, Toby King, Thomas F Koinis, Jennifer Scott Koontz, Martin Kužma, Carleen Lindsey, Mattias Lorentzon, George P Lyritis, Laura Boehnke Michaud, Armando Miciano, Suzanne N Morin, Nadia Mujahid, Nicola Napoli, Thomas P Olenginski, J Edward Puzas, Stavroula Rizou, Clifford J Rosen, Kenneth Saag, Elizabeth Thompson, Laura L Tosi, Howard Tracer, Sundeep Khosla, Douglas P Kiel. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020 01; 35(1):36-52. doi: 10.1002/jbmr.3877. [PMID: 31538675]
Fanguo Kong, Bin Jia, Peng Cui, Duojun Wang. Novel combinatorial transdermal drug delivery of alendronate with risedronate for the treatment of osteoporosis. Acta biochimica Polonica. 2019 Dec; 66(4):463-467. doi: 10.18388/abp.2019_2863. [PMID: 31846272]
So Young Park, Moo-Il Kang, Hyung Moo Park, Yumie Rhee, Seong Hwan Moon, Hyun Koo Yoon, Jung-Min Koh, Jae Suk Chang, In Joo Kim, Ye Yeon Won, Ye Soo Park, Hoon Choi, Chan Soo Shin, Taek Rim Yoon, Sung-Cheol Yun, Ho-Yeon Chung. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis. Archives of osteoporosis. 2019 12; 15(1):3. doi: 10.1007/s11657-019-0663-5. [PMID: 31820121]
Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
Toshitsugu Sugimoto, Daisuke Inoue, Masayuki Maehara, Ichiro Oikawa, Takashi Shigematsu, Yoshiki Nishizawa. Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan. Journal of bone and mineral metabolism. 2019 Jul; 37(4):730-740. doi: 10.1007/s00774-018-0977-1. [PMID: 30523414]
Yosra S R Elnaggar, Sara Omran, Heba A Hazzah, Ossama Y Abdallah. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate. International journal of pharmaceutics. 2019 Jun; 564(?):410-425. doi: 10.1016/j.ijpharm.2019.04.069. [PMID: 31029657]
Salvatore Minisola, Fernando Marin, David L Kendler, Piet Geusens, Cristiano A F Zerbini, Luis A Russo, Enrique Casado, Astrid Fahrleitner-Pammer, Jan J Stepan, Eric Lespessailles, Rüdiger Moericke, Alicia Bagur, Péter Lakatos, Pedro López-Romero, Jean Jacques Body. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. Archives of osteoporosis. 2019 01; 14(1):10. doi: 10.1007/s11657-019-0561-x. [PMID: 30659410]
Ryo Okazaki, Ryoichi Muraoka, Masayuki Maehara, Daisuke Inoue. Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis. Journal of bone and mineral metabolism. 2019 Jan; 37(1):185-197. doi: 10.1007/s00774-018-0931-2. [PMID: 29737412]
Dhrubojyoti Mukherjee, Bharath Srinivasan, J Anbu, Mohammad Azamthulla, Venkatesh Teja Banala, S G Ramachandra. Improvement of bone microarchitecture in methylprednisolone induced rat model of osteoporosis by using thiolated chitosan-based risedronate mucoadhesive film. Drug development and industrial pharmacy. 2018 Nov; 44(11):1845-1856. doi: 10.1080/03639045.2018.1503297. [PMID: 30028215]
Tomohiko Urano, Masataka Shiraki, Tatsuhiko Kuroda, Shiro Tanaka, Fumihiko Urano, Kazuhiro Uenishi, Satoshi Inoue. Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women. Journal of bone and mineral metabolism. 2018 Nov; 36(6):734-740. doi: 10.1007/s00774-017-0891-y. [PMID: 29236162]
T Ishida, S Yoshida, Y Kimura, Y Fujiki, T Kotani, T Takeuchi, S Makino, S Arawaka. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study. Lupus. 2018 Sep; 27(10):1636-1643. doi: 10.1177/0961203318784649. [PMID: 29954283]
Uwe Lange, Katharina Classen, Ulf Müller-Ladner, Manfred Richter. Weekly oral bisphosphonates over 2 years prevent bone loss in cardiac transplant patients. Clinical transplantation. 2017 Nov; 31(11):. doi: 10.1111/ctr.13122. [PMID: 28940569]
Yair Liel, Ygal Plakht, Muhammad Abu Tailakh. BONE TURNOVER IN OSTEOPOROTIC WOMEN DURING LONG-TERM ORAL BISPHOSPHONATES TREATMENT: IMPLICATIONS FOR TREATMENT FAILURE AND 'DRUG HOLIDAY' IN THE REAL WORLD. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2017 Jul; 23(7):787-793. doi: 10.4158/ep171781.or. [PMID: 28448762]
Satoshi Soen, Takashi Umemura, Tsuyoshi Ando, Toshiaki Kamisaki, Masahiko Nishikawa, Ryoichi Muraoka, Yoshinori Ikeda, Kyoko Takeda, Mitsuharu Osawa, Toshitaka Nakamura. Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice. Journal of bone and mineral metabolism. 2017 Jul; 35(4):419-427. doi: 10.1007/s00774-016-0771-x. [PMID: 27565972]
T Mawatari, R Muraoka, Y Iwamoto. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017 04; 28(4):1279-1286. doi: 10.1007/s00198-016-3848-4. [PMID: 27900428]
Takashi Shigematsu, Ryoichi Muraoka, Toshitsugu Sugimoto, Yoshiki Nishizawa. Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials. BMC nephrology. 2017 Feb; 18(1):66. doi: 10.1186/s12882-017-0478-9. [PMID: 28201994]
Joanna Kolmas, Kamil Pajor, Lukasz Pajchel, Agata Przekora, Grażyna Ginalska, Ewa Oledzka, Marcin Sobczak. Fabrication and physicochemical characterization of porous composite microgranules with selenium oxyanions and risedronate sodium for potential applications in bone tumors. International journal of nanomedicine. 2017; 12(?):5633-5642. doi: 10.2147/ijn.s140935. [PMID: 28848343]
Marta Rusek, Jolanta Elżbieta Pastryk, Jerzy Bełtowski. Modulation of paraoxonase 1 (PON1) activity and protein N-homocysteinylation by bisphosphonates in rats. Chemico-biological interactions. 2016 Nov; 259(Pt B):401-406. doi: 10.1016/j.cbi.2016.07.002. [PMID: 27387541]
Tetsuo Nakano, Masao Yamamoto, Junko Hashimoto, Masato Tobinai, Seitaro Yoshida, Toshitaka Nakamura. Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study. Journal of bone and mineral metabolism. 2016 Nov; 34(6):678-684. doi: 10.1007/s00774-015-0717-8. [PMID: 26462480]
M L Guzman, E A Soria, C Laino, R H Manzo, M E Olivera. Reduced food interaction and enhanced gastrointestinal tolerability of a new system based on risedronate complexed with Eudragit E100: Mechanistic approaches from in vitro and in vivo studies. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2016 Oct; 107(?):263-72. doi: 10.1016/j.ejpb.2016.07.012. [PMID: 27418392]
Muhammad Khurram Shahzad, Tali Hussain, Sabiha Karim, Nasir Abbas, Nadeem Irfan Bukhari. RELATIVE BIOAVAILABILITY OF RISEDRONATE SODIUM ADMINISTERED IN SUPERABSORBENT COPOLYMER PARTICLES VERSUS ORAL SOLUTION TO NORMAL HEALTHY RABBITS. Acta poloniae pharmaceutica. 2016 Sep; 73(5):1267-1274. doi: NULL. [PMID: 29638067]
Laura D Bilek, Nancy L Waltman, Joan M Lappe, Kevin A Kupzyk, Lynn R Mack, Diane M Cullen, Kris Berg, Meghan Langel, Melissa Meisinger, Ashlee Portelli-Trinidad, Molly Lang. Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women. BMC women's health. 2016 08; 16(1):59. doi: 10.1186/s12905-016-0339-x. [PMID: 27576310]
Deepak Kumar Khajuria, Choudhary Disha, Ramakrishna Vasireddi, Rema Razdan, D Roy Mahapatra. Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis. Materials science & engineering. C, Materials for biological applications. 2016 Jun; 63(?):78-87. doi: 10.1016/j.msec.2016.02.062. [PMID: 27040198]
Jeong S Kim, Sun W Jang, Miwon Son, Byoung M Kim, Myung J Kang. Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2016 Jan; 82(?):45-51. doi: 10.1016/j.ejps.2015.11.011. [PMID: 26594027]
Zeev Feldbrin, Alla Luckish, Marina Shargorodsky. Effects of long-term risedronate treatment on serum ferritin levels in postmenopausal women with osteoporosis: the impact of cardiovascular risk factor load. Menopause (New York, N.Y.). 2016 Jan; 23(1):55-9. doi: 10.1097/gme.0000000000000480. [PMID: 26057821]
Akihisa Itoh, Yuuki Akagi, Hitoshi Shimomura, Takao Aoyama. Interaction between Bisphosphonates and Mineral Water: Study of Oral Risedronate Absorption in Rats. Biological & pharmaceutical bulletin. 2016; 39(3):323-8. doi: 10.1248/bpb.b15-00630. [PMID: 26934925]
Yong Yang, Cai Liu, Yifan Zhang, Lei Zhou, Dafang Zhong, Xiaoyan Chen. On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method. Journal of pharmaceutical and biomedical analysis. 2015 Oct; 114(?):408-15. doi: 10.1016/j.jpba.2015.05.038. [PMID: 26117452]
Masaya Ohara, Yasuo Imanishi, Yuki Nagata, Akira Ishii, Ikue Kobayashi, Katsuhito Mori, Manabu Ito, Takami Miki, Yoshiki Nishizawa, Masaaki Inaba. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone. Journal of bone and mineral metabolism. 2015 Sep; 33(5):584-90. doi: 10.1007/s00774-014-0623-5. [PMID: 25319558]
Ana Sánchez-Escuredo, David Fuster, Domenico Rubello, Africa Muxí, Ana Ramos, Francisco Campos, Maria Cristina Marzola, Gary J Cook, Andrés Tapias, José-Vicente Torregrosa. Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients. Nuclear medicine communications. 2015 Aug; 36(8):815-8. doi: 10.1097/mnm.0000000000000316. [PMID: 25856225]
Keijiro Mukaiyama, Mikio Kamimura, Shigeharu Uchiyama, Shota Ikegami, Yukio Nakamura, Hiroyuki Kato. Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging clinical and experimental research. 2015 Aug; 27(4):413-8. doi: 10.1007/s40520-014-0296-x. [PMID: 25534961]
Aydan Oral, Roman Lorenc. Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study. Acta orthopaedica et traumatologica turcica. 2015; 49(1):67-74. doi: 10.3944/aott.2015.14.0082. [PMID: 25803256]
Ling-Xiao Chen, Zhi-Rui Zhou, Yu-Lin Li, Guang-Zhi Ning, Tian-Song Zhang, Di Zhang, Shi-Qing Feng. Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis. PloS one. 2015; 10(5):e0128032. doi: 10.1371/journal.pone.0128032. [PMID: 26010450]
Young Hwan Seo, Yoon Hee Chung, Cheol-Hee Lim, Ji Hoon Jeong. UPLC-UV method for determination of risedronate in human urine. Journal of chromatographic science. 2014 Aug; 52(7):713-8. doi: 10.1093/chromsci/bmt105. [PMID: 23851998]
J P Brown, C Roux, P R Ho, M A Bolognese, J Hall, H G Bone, S Bonnick, J P van den Bergh, I Ferreira, P Dakin, R B Wagman, C Recknor. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2014 Jul; 25(7):1953-61. doi: 10.1007/s00198-014-2692-7. [PMID: 24676847]
Shiro Tanaka, Teruhiko Miyazaki, Yukari Uemura, Tatsuhiko Kuroda, Nobuaki Miyakawa, Toshitaka Nakamura, Masao Fukunaga, Yasuo Ohashi, Hiroaki Ohta, Satoshi Mori, Hiroshi Hagino, Takayuki Hosoi, Toshitsugu Sugimoto, Eiji Itoi, Hajime Orimo, Masataka Shiraki. Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Journal of bone and mineral metabolism. 2014 May; 32(3):298-304. doi: 10.1007/s00774-013-0491-4. [PMID: 23828145]
Yuji Kasukawa, Naohisa Miyakoshi, Toshihito Ebina, Toshiaki Aizawa, Michio Hongo, Koji Nozaka, Yoshinori Ishikawa, Hidetomo Saito, Shuichi Chida, Yoichi Shimada. Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. Journal of bone and mineral metabolism. 2014 May; 32(3):290-7. doi: 10.1007/s00774-013-0490-5. [PMID: 23846118]
R Simanjuntak, E Setiawati, D A Yunaidi, L R Handayani, A Setiawati, B S Utami, T A Rosa, A B Sholeh. Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers. Drug research. 2014 Mar; 64(3):136-40. doi: 10.1055/s-0033-1354365. [PMID: 24002927]
David Banji, Otilia J F Banji, Vijaya Laxmi Chiluka, Saidulu Abbagoni. Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats. Indian journal of experimental biology. 2014 Feb; 52(2):153-8. doi: NULL. [PMID: 24597148]
Yohann Bala, Roland Chapurlat, Angela M Cheung, Dieter Felsenberg, Michel LaRoche, Edward Morris, Jonathan Reeve, Thierry Thomas, Jose Zanchetta, Oliver Bock, Ali Ghasem-Zadeh, Roger Martin Zebaze Djoumessi, Ego Seeman, René Rizzoli. Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2014 Feb; 29(2):380-8. doi: 10.1002/jbmr.2101. [PMID: 24115129]
Il-Woo Jung, Hyo-Kyung Han. Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization. International journal of nanomedicine. 2014; 9(?):2299-306. doi: 10.2147/ijn.s61181. [PMID: 24872692]
Naglaa F Khedr, Nahla E El-Ashmawy, Hoda A El-Bahrawy, Ali A Haggag, Eman E El-Abd. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. Fundamental & clinical pharmacology. 2013 Oct; 27(5):526-34. doi: 10.1111/j.1472-8206.2012.01047.x. [PMID: 22762129]
Jean-Pierre Devogelaer, Philip Sambrook, David M Reid, Stefan Goemaere, Sophia Ish-Shalom, Julien Collette, Guoqin Su, Christina Bucci-Rechtweg, Philemon Papanastasiou, Jean-Yves Reginster. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology (Oxford, England). 2013 Jun; 52(6):1058-69. doi: 10.1093/rheumatology/kes410. [PMID: 23365149]
Richard Choo, Himu Lukka, Patrick Cheung, Tom Corbett, Rosario Briones-Urbina, Reinhold Vieth, Lisa Ehrlich, Alex Kiss, Cyril Danjoux. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy. International journal of radiation oncology, biology, physics. 2013 Apr; 85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007. [PMID: 23265571]
Yoshihiro Nishida, Yoshihisa Yamada, Satoshi Tsukushi, Hideshi Sugiura, Hiroshi Urakawa, Naoki Ishiguro. Midterm outcome of risedronate therapy for patients with Paget's disease of bone in the central part of Japan. Clinical rheumatology. 2013 Feb; 32(2):241-5. doi: 10.1007/s10067-012-2109-y. [PMID: 23138882]
Ho Yeon Chung, Jawon Koo, Su Kyoung Kwon, Moo-Il Kang, Seong-Hwan Moon, Jin-Young Park, Chan Soo Shin, Byung-Koo Yoon, Hyun-Koo Yoon, Jae-Suk Chang, Yoon-Sok Chung, Hyoung-Moo Park. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis. Clinical interventions in aging. 2013; 8(?):597-603. doi: 10.2147/cia.s44395. [PMID: 23761968]
J S Thomsen, T S Straarup, C C Danielsen, H Oxlund, A Brüel. No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis. Scandinavian journal of rheumatology. 2013; 42(5):408-16. doi: 10.3109/03009742.2013.774046. [PMID: 23527881]
Pilar Peris, Elizabeth J Atkinson, Mario Gössl, Trevor L Kane, Louise K McCready, Amir Lerman, Sundeep Khosla, Ulrike I McGregor. Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women. Mayo Clinic proceedings. 2013 Jan; 88(1):46-55. doi: 10.1016/j.mayocp.2012.08.019. [PMID: 23228561]
Valeria Cohran, Amy Cassedy, Andre Hawkins, Judy Bean, James Heubi. Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial. Journal of pediatric rehabilitation medicine. 2013; 6(2):85-93. doi: 10.3233/prm-130242. [PMID: 23803341]
Sung Jin Bae, Beom-Jun Kim, Kyeong Hye Lim, Seung Hun Lee, Hong Kyu Kim, Ghi Su Kim, Jung-Min Koh. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. Journal of bone and mineral metabolism. 2012 Sep; 30(5):588-95. doi: 10.1007/s00774-012-0361-5. [PMID: 22610063]
Catherine Van Poznak, Andreas Makris, Glen Clack, David H Barlow, Richard Eastell. Lipid profiles within the SABRE trial of anastrozole with and without risedronate. Breast cancer research and treatment. 2012 Aug; 134(3):1141-7. doi: 10.1007/s10549-012-2147-9. [PMID: 22763465]
Maria Coco, James Pullman, Hillel W Cohen, Sally Lee, Craig Shapiro, Clemencia Solorzano, Stuart Greenstein, Daniel Glicklich. Effect of risedronate on bone in renal transplant recipients. Journal of the American Society of Nephrology : JASN. 2012 Aug; 23(8):1426-37. doi: 10.1681/asn.2011060623. [PMID: 22797188]
M L Frost, M Siddique, G M Blake, A E Moore, P K Marsden, P J Schleyer, R Eastell, I Fogelman. Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Aug; 23(8):2107-16. doi: 10.1007/s00198-011-1805-9. [PMID: 21983795]
Pilar Peris, Angeles Martínez-Ferrer, Ana Monegal, M Jesús Martínez de Osaba, Africa Muxi, Nuria Guañabens. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone. 2012 Jul; 51(1):54-8. doi: 10.1016/j.bone.2012.03.026. [PMID: 22487299]
R Okazaki, H Hagino, M Ito, T Sone, T Nakamura, H Mizunuma, M Fukunaga, M Shiraki, Y Nishizawa, Y Ohashi, T Matsumoto. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Jun; 23(6):1737-45. doi: 10.1007/s00198-011-1782-z. [PMID: 21932114]
José V Torregrosa, Carlos E Durán, Xoana Barros, Miquel Blasco, Marta Arias, Aleix Cases, Josep M Campistol. Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2012 May; 32(3):329-34. doi: 10.3265/nefrologia.pre2012.jan.11137. [PMID: 22592420]
Murat Zinnuroglu, Aylin Sepici Dincel, Funda Kosova, Vesile Sepici, Gulcin Kaymak Karatas. Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis. Rheumatology international. 2012 Apr; 32(4):875-80. doi: 10.1007/s00296-010-1708-7. [PMID: 21221594]
Yu Chen, Yuxiu Liu, Zhidong Chen, Meilan Chen, Yan Zhu. [Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection]. Se pu = Chinese journal of chromatography. 2012 Apr; 30(4):414-8. doi: 10.3724/sp.j.1123.2011.12070. [PMID: 22799202]
C Roux, D M Reid, J-P Devogelaer, K Saag, C S Lau, J-Y Reginster, P Papanastasiou, C Bucci-Rechtweg, G Su, P N Sambrook. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Mar; 23(3):1083-90. doi: 10.1007/s00198-011-1800-1. [PMID: 21975559]
S A Polyzos, A D Anastasilakis, C Bratengeier, W Woloszczuk, A Papatheodorou, E Terpos. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Mar; 23(3):1171-6. doi: 10.1007/s00198-010-1525-6. [PMID: 21305266]
Jehoon Lee, Samuel Vasikaran. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Annals of laboratory medicine. 2012 Mar; 32(2):105-12. doi: 10.3343/alm.2012.32.2.105. [PMID: 22389876]
Xueyan Fu, Judith Moreines, Sarah L Booth. Vitamin K supplementation does not prevent bone loss in ovariectomized Norway rats. Nutrition & metabolism. 2012 Feb; 9(1):12. doi: 10.1186/1743-7075-9-12. [PMID: 22348311]
Sussan Ghassabian, Linda A Wright, Andrew D Dejager, Maree T Smith. Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Jan; 881-882(?):34-41. doi: 10.1016/j.jchromb.2011.11.031. [PMID: 22197608]
L A Bradbury, S Barlow, F Geoghegan, R A Hannon, S L Stuckey, J A H Wass, R G G Russell, M A Brown, E L Duncan. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Jan; 23(1):285-94. doi: 10.1007/s00198-011-1658-2. [PMID: 21739105]
Masayuki Takakuwa, Jun Iwamoto. Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. Biological & pharmaceutical bulletin. 2012; 35(7):1159-65. doi: 10.1248/bpb.b12-00200. [PMID: 22791166]
Terry J Aspray, Roger M Francis. Treatment of osteoporosis in women intolerant of oral bisphosphonates. Maturitas. 2012 Jan; 71(1):76-8. doi: 10.1016/j.maturitas.2011.10.005. [PMID: 22079368]
Natalya A Muraleva, Evgeniy N Ofitserov, Vladimir P Tikhonov, Natalya G Kolosova. Efficacy of glucosamine alendronate alone & in combination with dihydroquercetin for treatment of osteoporosis in animal model. The Indian journal of medical research. 2012; 135(?):221-7. doi: NULL. [PMID: 22446865]
K Amagase, A Inaba, T Senta, Y Ishikawa, K Nukui, T Murakami, Koji Takeuchi. Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2011 Dec; 62(6):609-18. doi: . [PMID: 22314563]
Sydney Lou Bonnick. Going on a drug holiday?. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2011 Oct; 14(4):377-83. doi: 10.1016/j.jocd.2011.07.006. [PMID: 22051091]
P S M Lai, S S Chua, Y Y Chew, S P Chan. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. Journal of clinical pharmacy and therapeutics. 2011 Oct; 36(5):557-67. doi: 10.1111/j.1365-2710.2010.01210.x. [PMID: 21916908]
P Peris, M Torra, V Olivares, R Reyes, A Monegal, A Martínez-Ferrer, N Guañabens. Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover. Bone. 2011 Oct; 49(4):706-9. doi: 10.1016/j.bone.2011.06.027. [PMID: 21742070]
K Izumi, A Mizokami, K Sugimoto, K Narimoto, Y Kitagawa, E Koh, M Namiki. Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study. Prostate cancer and prostatic diseases. 2011 Sep; 14(3):238-42. doi: 10.1038/pcan.2011.10. [PMID: 21423267]
Ian R Reid, Kenneth Lyles, Guoqin Su, Jacques P Brown, John P Walsh, Javier del Pino-Montes, Paul D Miller, William D Fraser, Susan Cafoncelli, Christina Bucci-Rechtweg, David J Hosking. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011 Sep; 26(9):2261-70. doi: 10.1002/jbmr.438. [PMID: 21638319]
Danielle A Eekman, Irene E M Bultink, Annemieke C Heijboer, Ben A C Dijkmans, Willem F Lems. Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC musculoskeletal disorders. 2011 Jul; 12(?):167. doi: 10.1186/1471-2474-12-167. [PMID: 21774839]
Sonsoles Guadalix, Guillermo Martínez-Díaz-Guerra, David Lora, Carmela Vargas, Miren Gómez-Juaristi, Belén Cobaleda, Enrique Moreno González, Federico Hawkins. Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. Transplant international : official journal of the European Society for Organ Transplantation. 2011 Jul; 24(7):657-65. doi: 10.1111/j.1432-2277.2011.01253.x. [PMID: 21466595]
Glen M Blake, Michelle L Frost, Amelia E B Moore, Musib Siddique, Ignac Fogelman. The assessment of regional skeletal metabolism: studies of osteoporosis treatments using quantitative radionuclide imaging. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2011 Jul; 14(3):263-71. doi: 10.1016/j.jocd.2011.04.003. [PMID: 21600822]
Ho-Yeon Chung, Sang Ouk Chin, Moo-I L Kang, Jung-Min Koh, Sung-Hwan Moon, Byung-Koo Yoon, Hyun-Koo Yoon, Yoon-Sok Chung, Hyoung-Moo Park. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. Clinical endocrinology. 2011 Jun; 74(6):699-704. doi: 10.1111/j.1365-2265.2011.04041.x. [PMID: 21521310]
Carolyn J Crandall, Chi-Hong Tseng, Sybil L Crawford, Rebecca C Thurston, Ellen B Gold, Janet M Johnston, Gail A Greendale. Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011 Apr; 26(4):840-9. doi: 10.1002/jbmr.259. [PMID: 20878774]
Suruchi Khanna, Krishna K Pillai, Divya Vohora. Bisphosphonates in phenytoin-induced bone disorder. Bone. 2011 Mar; 48(3):597-606. doi: 10.1016/j.bone.2010.10.172. [PMID: 21040807]
Mohammad Shahnazari, Wei Yao, Bob Wang, Brian Panganiban, Robert O Ritchie, Yolanda Hagar, Nancy E Lane. Differential maintenance of cortical and cancellous bone strength following discontinuation of bone-active agents. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011 Mar; 26(3):569-81. doi: 10.1002/jbmr.249. [PMID: 20839286]
W Mahmood, M J McKenna. Proposed new approach for treating Paget's disease of bone. Irish journal of medical science. 2011 Mar; 180(1):121-4. doi: 10.1007/s11845-010-0652-6. [PMID: 21132539]
Laëtitia Michou, Jacques P Brown. Emerging strategies and therapies for treatment of Paget's disease of bone. Drug design, development and therapy. 2011; 5(?):225-39. doi: 10.2147/dddt.s11306. [PMID: 21607019]
Pawel Szulc. Biochemical bone turnover markers and osteoporosis in older men: where are we?. Journal of osteoporosis. 2011; 2011(?):704015. doi: 10.4061/2011/704015. [PMID: 22220284]
Hisaya Kawate, Ryoichi Takayanagi. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clinical interventions in aging. 2011; 6(?):151-60. doi: 10.2147/cia.s15711. [PMID: 21753870]
S A Polyzos, J Kountouras, A D Anastasilakis, I Litsas, M Kita, G Arsos, E Moralidis, E Terpos. Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2011 Jan; 22(1):363-7. doi: 10.1007/s00198-010-1230-5. [PMID: 20407889]
Ayse Arslan, Sevim Orkun, Gülümser Aydin, Isik Keles, Aliye Tosun, Mustafa Arslan, Osman Caglayan. Effects of ovariectomy and ascorbic acid supplement on oxidative stress parameters and bone mineral density in rats. The Libyan journal of medicine. 2011; 6(?):. doi: 10.3402/ljm.v6i0.5965. [PMID: 21980320]
Julio Rubio, Wang Qiong, Xinmin Liu, Zhen Jiang, Haixia Dang, Shi-Lin Chen, Gustavo F Gonzales. Aqueous Extract of Black Maca (Lepidium meyenii) on Memory Impairment Induced by Ovariectomy in Mice. Evidence-based complementary and alternative medicine : eCAM. 2011; 2011(?):253958. doi: 10.1093/ecam/nen063. [PMID: 18955369]